All trades / PTCT
PTCT
PTC THERAPEUTICS, INC.
896Open-market trades
+24.6%Avg 90d after buys
+3.56%Avg 90d after sales
+17.9%Avg 180d after buys
Price and insider prints
PTCT adjusted close▲ buy▼ sale
Trades
| Date | Form 4 | Ticker | Insider | Title | Side | Shares | Value | 90d | 180d |
|---|---|---|---|---|---|---|---|---|---|
| 9/17/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 376 | $25.7K | +17.9%hist | +24.3%hist |
| 9/17/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 9,624 | $652.8K | +17.9%hist | +24.3%hist |
| 9/16/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 7,006 | $471.9K | +17.9%hist | +24.3%hist |
| 9/16/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 2,994 | $199.3K | +17.9%hist | +24.3%hist |
| 9/10/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 10,000 | $673.4K | +17.9%hist | +24.3%hist |
| 9/9/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 572 | $39.3K | +17.9%hist | +24.3%hist |
| 9/9/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 9,428 | $639.1K | +17.9%hist | +24.3%hist |
| 8/27/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 11,890 | $850.7K | +17.9%hist | +24.3%hist |
| 8/27/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 610 | $44.1K | +17.9%hist | +24.3%hist |
| 8/26/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 6,874 | $500.0K | +17.9%hist | +24.3%hist |
| 8/26/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 5,626 | $411.7K | +17.9%hist | +24.3%hist |
| 8/20/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 9,419 | $666.7K | +17.9%hist | +24.3%hist |
| 8/20/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 2,390 | $171.8K | +17.9%hist | +24.3%hist |
| 8/20/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 691 | $50.4K | +17.9%hist | +24.3%hist |
| 8/19/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 5,335 | $388.7K | +17.9%hist | +24.3%hist |
| 8/19/2026 | Form 4 | PTCT 10b5-1 | SCHMERTZLER MICHAELMr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, from 2018 to 2025, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company; as Executive Chairman of Berryville Holdings and Dispel LLC, private cyber-technology companies; and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr.… | Director | SELL | 7,165 | $527.8K | +17.9%hist | +24.3%hist |
| 8/17/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 969 | $70.6K | +5.93%hist | −2.24%hist |
| 8/17/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 1,844 | $133.5K | +5.93%hist | −2.24%hist |
| 8/4/2026 | Form 4 | PTCT 10b5-1 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 10,292 | $705.7K | +1.55%hist | −1.13%hist |
| 7/14/2026 | Form 4 | PTCT 10b5-1 | Gravier PierreMr. Gravier has served as our Chief Financial Officer since July 2023. Prior to joining the Company, Mr. Gravier served as Managing Director of Perella Weinberg Partners, or Perella Weinberg, a global independent investment banking firm, from 2013 to July 2023. While employed at Perella Weinberg, Mr. Gravier focused on the biopharmaceutical and pharmaceutical services sectors, advising clients on a range of transactions including mergers and acquisitions, joint ventures and licensing arrangements, and capital raises across the equity, debt, royalty and convertible securities markets. Mr. Gravier has served as a member of the board of directors of Cassava Sciences, Inc., a Nasdaq-listed biopharmaceutical… | CHIEF FINANCIAL OFFICER | SELL | 3,494 | $280.7K | −1.78%hist | −8.81%hist |
| 7/9/2026 | Form 4 | PTCT 10b5-1 | Smith Mary L.Ms. Smith has served as a member of our Board since 2021. Since February 2018, Ms. Smith has served as Vice Chair at the VENG Group, a non-partisan government relations and public affairs firm, consulting clients on business development, strategy, healthcare and corporate governance. Ms. Smith served as Principal Deputy Director (Chief Executive Officer equivalent) from March 2016 to January 2017 and Deputy Director from October 2015 to March 2016 of Indian Health Service, a division of the U.S. Department of Health and Human Services and system of hospitals providing healthcare to over 2.2 million Native Americans in the United States. From July 2014 to April 2015, Ms. Smith served as Special Counsel &… | Director | SELL | 5,834 | $525.1K | — | — |
| 7/9/2026 | Form 4 | PTCT 10b5-1 | Smith Mary L.Ms. Smith has served as a member of our Board since 2021. Since February 2018, Ms. Smith has served as Vice Chair at the VENG Group, a non-partisan government relations and public affairs firm, consulting clients on business development, strategy, healthcare and corporate governance. Ms. Smith served as Principal Deputy Director (Chief Executive Officer equivalent) from March 2016 to January 2017 and Deputy Director from October 2015 to March 2016 of Indian Health Service, a division of the U.S. Department of Health and Human Services and system of hospitals providing healthcare to over 2.2 million Native Americans in the United States. From July 2014 to April 2015, Ms. Smith served as Special Counsel &… | Director | SELL | 10,000 | $900.0K | — | — |
| 7/9/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 2,464 | $222.4K | +4.62%hist | +6.86%hist |
| 7/7/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 3,956 | $344.8K | +4.62%hist | +6.86%hist |
| 7/7/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 11,369 | $1.01M | +4.62%hist | +6.86%hist |
| 7/7/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 9,288 | $830.7K | +4.62%hist | +6.86%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 313 | $26.0K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 833 | $70.3K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 519 | $44.6K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 601 | $51.9K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 387 | $32.2K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 1,036 | $87.4K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 645 | $55.4K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 745 | $64.4K | +5.93%hist | −2.24%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 426 | $36.3K | +4.62%hist | +6.86%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 385 | $33.2K | +4.62%hist | +6.86%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 8,786 | $749.9K | +4.62%hist | +6.86%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 10,090 | $871.0K | +4.62%hist | +6.86%hist |
| 7/6/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 2,474 | $215.3K | +4.62%hist | +6.86%hist |
| 6/26/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 412 | $35.1K | +4.62%hist | +6.86%hist |
| 6/26/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 7,718 | $658.0K | +4.62%hist | +6.86%hist |
| 6/25/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 582 | $49.6K | +4.62%hist | +6.86%hist |
| 6/25/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 100 | $8.7K | +4.62%hist | +6.86%hist |
| 6/25/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 11,337 | $980.8K | +4.62%hist | +6.86%hist |
| 6/25/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 8,522 | $726.6K | +4.62%hist | +6.86%hist |
| 6/25/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 419 | $36.2K | +4.62%hist | +6.86%hist |
| 6/24/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 4,922 | $418.5K | +4.62%hist | +6.86%hist |
| 6/24/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 401 | $34.1K | +4.62%hist | +6.86%hist |
| 6/22/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 12,130 | $977.8K | +4.62%hist | +6.86%hist |
| 6/22/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 11,619 | $943.6K | +4.62%hist | +6.86%hist |
| 6/17/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 1,850 | $146.6K | +16.4% | −2.24%hist |
| 6/17/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 1,703 | $133.7K | +16.4% | −2.24%hist |
| 6/17/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 309 | $24.5K | +16.4% | −2.24%hist |
| 6/17/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 6,600 | $518.1K | +16.4% | −2.24%hist |
| 6/17/2026 | Form 4 | PTCT 10b5-1 | Utter Christine MarieMs. Utter has served as our Chief Accounting Officer since June 2019. Ms. Utter joined the Company in 2010 as the Assistant Controller, became Senior Vice President, Finance, in January 2017 and Principal Financial Officer in June 2017 and served in such capacity until June 2019. From 2005 until 2009, Ms. Utter was the Assistant Corporate Controller of Barrier Therapeutics. Prior to 2005, Ms. Utter held positions as a financial analyst at Engelhard Corporation and as an auditor at both Ernst & Young LLP and Arthur Andersen. Ms. Utter holds a B.S. in accounting from The College of New Jersey and is a certified public accountant. There are no family relationships between or among any of our executive officers… | SVP, CHIEF ACCOUNTING OFFICER | SELL | 19,686 | $1.49M | +16.4% | +7.91%hist |
| 6/10/2026 | Form 4 | PTCT 10b5-1 | Pauwels EricMr. Pauwels has served as our Chief Business Officer since April 2020. Mr. Pauwels has 40 years of healthcare experience in biopharmaceuticals and medical devices. Mr. Pauwels joined the Company in March 2015 as Senior Vice President and General Manager of the Americas. He also serves as a director of one of our subsidiaries. From September 2011 until March 2015, Mr. Pauwels was the Chief Commercial Officer and President of International for NPS Pharmaceuticals, a publicly traded biopharmaceutical company that was acquired by Shire plc. In 2011, Mr. Pauwels was the Chief Marketing Officer of Accuray Inc. From 2005 to 2010 Mr. Pauwels served as the first Chief Commercial Officer for Shire Human Genetic… | CHIEF BUSINESS OFFICER | SELL | 3,711 | $278.3K | +6.19% | +3.74%hist |
| 6/10/2026 | Form 4 | PTCT 10b5-1 | Pauwels EricMr. Pauwels has served as our Chief Business Officer since April 2020. Mr. Pauwels has 40 years of healthcare experience in biopharmaceuticals and medical devices. Mr. Pauwels joined the Company in March 2015 as Senior Vice President and General Manager of the Americas. He also serves as a director of one of our subsidiaries. From September 2011 until March 2015, Mr. Pauwels was the Chief Commercial Officer and President of International for NPS Pharmaceuticals, a publicly traded biopharmaceutical company that was acquired by Shire plc. In 2011, Mr. Pauwels was the Chief Marketing Officer of Accuray Inc. From 2005 to 2010 Mr. Pauwels served as the first Chief Commercial Officer for Shire Human Genetic… | CHIEF BUSINESS OFFICER | SELL | 17,566 | $1.32M | +6.19% | +3.74%hist |
| 5/15/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 456 | $33.1K | −0.70% | −2.24%hist |
| 5/15/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 2,356 | $169.8K | −0.70% | −2.24%hist |
| 5/14/2026 | Form 4 | PTCT 10b5-1 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 7,221 | $527.7K | +0.11% | −1.13%hist |
| 5/14/2026 | Form 4 | PTCT 10b5-1 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 679 | $49.6K | +0.11% | −1.13%hist |
| 5/14/2026 | Form 4 | PTCT 10b5-1 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 2,100 | $153.5K | +0.11% | −1.13%hist |
| 5/14/2026 | Form 4 | PTCT 10b5-1 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 2,572 | $186.4K | +0.11% | −1.13%hist |
| 5/8/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 840 | $65.7K | +3.85% | −2.24%hist |
| 5/8/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 1,900 | $150.7K | +3.85% | −2.24%hist |
| 5/8/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 200 | $15.6K | +3.85% | −2.24%hist |
| 5/8/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 600 | $47.6K | +3.85% | −2.24%hist |
| 4/21/2026 | Form 4 | PTCT 10b5-1 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 2,850 | $202.1K | −10.4% | −1.13%hist |
| 4/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 822 | $56.6K | −24.0% | −2.24%hist |
| 4/6/2026 | Form 4 | PTCT 10b5-1 | Boulding Mark ElliottMr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and has previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two… | EXEC. VP AND CLO | SELL | 1,443 | $100.6K | −24.0% | −2.24%hist |
| 4/2/2026 | Form 4 | PTCT 10b5-1 | Golden Lee ScottDr. Golden has served as our Executive Vice President and Chief Medical Officer since April 2023 and previously served as our Chief Medical Officer from January 2022 to April 2023 and our SVP, Head of Global Clinical Development from May 2020 to January 2022. Prior to joining PTC, Dr. Golden served as Chief Medical Officer of Espero Pharmaceuticals, Inc, a former privately-held, development-stage cardiovascular pharmaceutical company, from October 2018 to May 2020 and as Chief Medical Officer of Gemphire Therapeutics, Inc., a former publicly traded clinical-stage biopharmaceutical company, from October 2016 to September 2018. Dr. Golden has also served on the board of directors of Coagulation Sciences LLC,… | EVP & CHIEF MEDICAL OFFICER | SELL | 829 | $56.4K | −20.0% | −11.8%hist |
| 4/1/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 39,393 | $2.71M | −18.6% | +6.86%hist |
| 4/1/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 80 | $5.6K | −18.6% | +6.86%hist |
| 4/1/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 12,530 | $870.8K | −18.6% | +6.86%hist |
| 3/12/2026 | Form 4 | PTCT 10b5-1 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | SELL | 2,662 | $170.6K | −15.8% | −8.60% |
| 3/10/2026 | Form 4 | PTCT 10b5-1 | Okey StephanieMs. Okey has served as a member of the board of directors of PTC Therapeutics, a Nasdaq-listed biopharmaceutical company. From March 2021 until May 2022, Ms. Okey served as a member of the board of directors of Orphazyme, a company based in Denmark. From August 2023 until acquisition by Novo Holdings in December 2024, Ms. Okey served on the board of directors of Catalent, Inc. Beginning February 2024 and ongoing, Ms. Okey serves on the board of directors of City of Hope Medical Center. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey received a B.S. degree in Zoology from The Ohio State University… | Director | SELL | 1,167 | $81.7K | −3.37% | −0.36% |
| 3/10/2026 | Form 4 | PTCT 10b5-1 | Okey StephanieMs. Okey has served as a member of the board of directors of PTC Therapeutics, a Nasdaq-listed biopharmaceutical company. From March 2021 until May 2022, Ms. Okey served as a member of the board of directors of Orphazyme, a company based in Denmark. From August 2023 until acquisition by Novo Holdings in December 2024, Ms. Okey served on the board of directors of Catalent, Inc. Beginning February 2024 and ongoing, Ms. Okey serves on the board of directors of City of Hope Medical Center. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey received a B.S. degree in Zoology from The Ohio State University… | Director | SELL | 14,000 | $980.0K | −3.37% | −0.36% |
| 3/5/2026 | Form 4 | PTCT 10b5-1 | Almstead Neil GregoryDr. Almstead has served as our Chief Technical Operations Officer since December 2018. Dr. Almstead has been employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders,… | CHIEF TECHNICAL OPS OFFICER | SELL | 3,989 | $252.8K | −8.45% | −11.4% |
| 3/5/2026 | Form 4 | PTCT 10b5-1 | Golden Lee ScottDr. Golden has served as our Executive Vice President and Chief Medical Officer since April 2023 and previously served as our Chief Medical Officer from January 2022 to April 2023 and our SVP, Head of Global Clinical Development from May 2020 to January 2022. Prior to joining PTC, Dr. Golden served as Chief Medical Officer of Espero Pharmaceuticals, Inc, a former privately-held, development-stage cardiovascular pharmaceutical company, from October 2018 to May 2020 and as Chief Medical Officer of Gemphire Therapeutics, Inc., a former publicly traded clinical-stage biopharmaceutical company, from October 2016 to September 2018. Dr. Golden has also served on the board of directors of Coagulation Sciences LLC,… | EVP & CHIEF MEDICAL OFFICER | SELL | 10,000 | $633.8K | −8.45% | −11.4% |
| 3/5/2026 | Form 4 | PTCT 10b5-1 | Okey StephanieMs. Okey has served as a member of the board of directors of PTC Therapeutics, a Nasdaq-listed biopharmaceutical company. From March 2021 until May 2022, Ms. Okey served as a member of the board of directors of Orphazyme, a company based in Denmark. From August 2023 until acquisition by Novo Holdings in December 2024, Ms. Okey served on the board of directors of Catalent, Inc. Beginning February 2024 and ongoing, Ms. Okey serves on the board of directors of City of Hope Medical Center. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey received a B.S. degree in Zoology from The Ohio State University… | Director | SELL | 6,333 | $401.4K | −8.45% | −11.4% |
Chart shows split-adjusted close for the last three years, or the selected date range. Triangles mark open-market Form 4 purchases and sales in that window.